

# Contents

<b>Preface</b>	viii
<b>Acknowledgments</b>	xi
<b>1 Introduction</b>	<b>1</b>
1.1 Correlated response data.....	1
1.1.1 Repeated measurements.....	1
1.1.2 Clustered data.....	2
1.1.3 Spatially correlated data.....	3
1.1.4 Multivariate data.....	4
1.2 Explanatory variables.....	4
1.3 Types of models.....	5
1.3.1 Marginal versus mixed-effects models.....	6
1.3.2 Models in SAS.....	7
1.3.3 Alternative approaches.....	10
1.4 Some examples.....	10
1.5 Summary features.....	19
<b>I Linear Models</b>	<b>21</b>
<b>2 Marginal Linear Models - Normal Theory</b>	<b>23</b>
2.1 The marginal linear model (LM).....	23
2.1.1 Estimation.....	25
2.1.2 Inference and test statistics.....	29
2.2 Examples.....	34
2.2.1 Dental growth data.....	34
2.2.2 Bone mineral density data.....	44

2.2.3 ADEMEX adequacy data .....	55
2.2.4 MCM2 biomarker data.....	58
2.3 Summary .....	66
<b>3 Linear Mixed-Effects Models - Normal Theory</b>	<b>67</b>
3.1 The linear mixed-effects (LME) model.....	68
3.1.1 Features of the LME model .....	69
3.1.2 Estimation.....	76
3.1.3 Inference and test statistics.....	77
3.2 Examples.....	79
3.2.1 Dental growth data - continued .....	79
3.2.2 Bone mineral density data - continued .....	81
3.2.3 Estrogen levels in healthy premenopausal women .....	83
3.3 Summary .....	98
<b>II Nonlinear Models</b>	<b>101</b>
<b>4 Generalized Linear and Nonlinear Models</b>	<b>103</b>
4.1 The generalized linear model (GLIM).....	104
4.1.1 Estimation and inference in the univariate case.....	106
4.2 The GLIM for correlated response data.....	109
4.2.1 Estimation.....	110
4.2.2 Inference and test statistics.....	115
4.2.3 Model selection and diagnostics.....	116
4.3 Examples of GLIM's .....	119
4.3.1 ADEMEX peritonitis infection data.....	119
4.3.2 Respiratory disorder data.....	125
4.3.3 Epileptic seizure data .....	129
4.3.4 Schizophrenia data.....	138
4.4 The generalized nonlinear model (GNLM).....	151
4.4.1 Normal-theory nonlinear model (NLM).....	153
4.4.2 Estimation.....	154
4.4.3 Inference and test statistics.....	160
4.5 Examples of GNLM's .....	164
4.5.1 LDH enzyme leakage data .....	164
4.5.2 Orange tree data .....	179
4.5.3 Respiratory disorder data - continued .....	188

4.5.4 Epileptic seizure data - continued .....	191
4.6 Computational considerations .....	201
4.6.1 Model parameterization and scaling .....	201
4.6.2 Starting values .....	202
4.7 Summary .....	203
<b>5 Generalized Linear and Nonlinear Mixed-Effects Models</b> .....	<b>205</b>
5.1 The generalized linear mixed-effects (GLME) model .....	206
5.1.1 Estimation .....	209
5.1.2 Comparing different estimators .....	216
5.1.3 Inference and test statistics .....	218
5.1.4 Model selection, goodness-of-fit and diagnostics .....	225
5.2 Examples of GLME models .....	226
5.2.1 Respiratory disorder data - continued .....	226
5.2.2 Epileptic seizure data - continued .....	235
5.2.3 Schizophrenia data - continued .....	245
5.2.4 ADEMEX hospitalization data .....	253
5.3 The generalized nonlinear mixed-effects (GNLME) model .....	264
5.3.1 Fully parametric GNLME models .....	265
5.3.2 Normal-theory nonlinear mixed-effects (NLME) model .....	267
5.3.3 Overcoming modeling limitations in SAS .....	269
5.3.4 Estimation .....	271
5.3.5 Comparing different estimators .....	282
5.3.6 Computational issues - starting values .....	285
5.3.7 Inference and test statistics .....	287
5.4 Examples of GNLME models .....	290
5.4.1 Orange tree data - continued .....	290
5.4.2 Soybean growth data .....	297
5.4.3 High flux hemodialyzer data .....	309
5.4.4 Cefamandole pharmacokinetic data .....	321
5.4.5 Epileptic seizure data - continued .....	328
5.5 Summary .....	332
<b>III Further Topics</b> .....	<b>335</b>
<b>6 Missing Data in Longitudinal Clinical Trials</b> .....	<b>337</b>
6.1 Background .....	337

6.2 Missing data mechanisms .....	338
6.2.1 Missing Completely at Random (MCAR) .....	340
6.2.2 Missing at Random (MAR).....	341
6.2.3 Missing Not at Random (MNAR) .....	342
6.3 Dropout mechanisms .....	345
6.3.1 Ignorable versus non-ignorable dropout.....	346
6.3.2 Practical issues with missing data and dropout.....	353
6.3.3 Developing an analysis plan for missing data .....	354
6.4 Methods of analysis under MAR .....	355
6.4.1 Likelihood-based methods.....	355
6.4.2 Imputation-based methods.....	356
6.4.3 Inverse probability of weighting (IPW) .....	361
6.4.4 Example: A repeated measures ANCOVA .....	364
6.5 Sensitivity analysis under MNAR .....	370
6.5.1 Selection models.....	371
6.5.2 Pattern mixture models .....	374
6.5.3 Shared parameter (SP) models .....	379
6.5.4 A repeated measures ANCOVA - continued .....	381
6.6 Missing data - case studies.....	385
6.6.1 Bone mineral density data - continued .....	385
6.6.2 MDRD study - GFR data.....	392
6.6.3 Schizophrenia data - continued .....	421
6.7 Summary .....	433
<b>7 Additional Topics and Applications</b> .....	<b>435</b>
7.1 Mixed models with non-Gaussian random effects .....	436
7.1.1 ADEMEX peritonitis and hospitalization data .....	437
7.2 Pharmacokinetic applications .....	446
7.2.1 Theophylline data .....	446
7.2.2 Phenobarbital data.....	456
7.3 Joint modeling of longitudinal data and survival data.....	468
7.3.1 ADEMEX study - GFR data and survival.....	468
<b>IV Appendices</b> .....	<b>491</b>
<b>A Some useful matrix notation and results</b> .....	<b>493</b>
A.1 Matrix notation and results.....	493

<b>B Additional results on estimation</b>	<b>497</b>
B.1 The different estimators for mixed-effects models .....	497
B.2 Comparing large sample properties of the different estimators.....	498
<b>C Datasets</b>	<b>510</b>
C.1 Dental growth data.....	510
C.2 Bone mineral density data.....	510
C.3 ADEMEX adequacy data.....	510
C.4 MCM2 biomarker data .....	510
C.5 Estrogen hormone data .....	510
C.6 ADEMEX peritonitis and hospitalization data .....	511
C.7 Respiratory disorder data.....	511
C.8 Epileptic seizure data.....	511
C.9 Schizophrenia data.....	511
C.10 LDH enzyme leakage data .....	511
C.11 Orange tree data .....	511
C.12 Soybean growth data.....	511
C.13 High flux hemodialyzer data.....	511
C.14 Cefamandole pharmacokinetic data .....	512
C.15 MDRD data .....	512
C.16 Theophylline data .....	512
C.17 Phenobarbital data .....	512
C.18 ADEMEX GFR and survival data.....	512
<b>D Select SAS macros</b>	<b>513</b>
D.1 The GOF Macro.....	513
D.2 The GLIMMIX_GOF Macro.....	513
D.3 The CCC Macro.....	513
D.4 The CONCORR Macro .....	513
D.5 The COVPARAMS Macro .....	513
D.6 The VECH Macro.....	513

